Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study - Alés-Martínez JE; Balmaña J; Sánchez-Rovira P; Salvador Bofill FJ; García Sáenz JÁ; Pimentel I; Morales S; Fernández-Abad M; Lahuerta Martínez A; Ferrer N; Zamora P; Bermejo B; et al. (2024)